General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase
- 1 September 1994
- journal article
- review article
- Published by Elsevier in General Pharmacology: The Vascular System
- Vol. 25 (5), 813-824
- https://doi.org/10.1016/0306-3623(94)90082-5
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Clinical pharmacology of the new COMT inhibitor CGP 28 014Neurochemical Research, 1993
- Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopaMovement Disorders, 1993
- Formation and Clearance of Interstitial Metabolites of Dopamine and Serotonin in the Rat Striatum: An In Vivo Microdialysis StudyJournal of Neurochemistry, 1992
- Extracellular Concentrations of Dopamine and Metabolites in the Rat Caudate After Oral Administration of a Novel Catechol‐O‐Methyltransferase Inhibitor Ro 40–7592Journal of Neurochemistry, 1992
- Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus MonkeysClinical Neuropharmacology, 1991
- Ro 40-7592Drugs of the Future, 1991
- Catechol‐O‐methyltransferase‐Inhibiting Pyrocatechol Derivatives: Synthesis and Structure‐Activity StudiesHelvetica Chimica Acta, 1989
- Synthesis of some novel potent and selective catechol O-methyltransferase inhibitorsJournal of Medicinal Chemistry, 1989
- Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the PrimateJournal of Neurochemistry, 1987
- Potentiation of the l-Dopa effect in man by the use of catechol-O-methyltransferase inhibitorsJournal of the Neurological Sciences, 1971